

human IL-6 Mouse mAb

human IL-6 Mouse mAb

Catalog # AP94142

Product Information

Application	WB, IHC-P, IHC-F, IF
Reactivity	Human
Host	Rabbit
Clonality	Monoclonal
Calculated MW	23 KDa
Physical State	Liquid
Immunogen	Recombinant human IL-6 protein
Epitope Specificity	30-212/212aa (C-6x His-Tag)
Isotype	IgG
Purity	affinity purified by Protein G
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SUBCELLULAR LOCATION	Secreted.
SIMILARITY	Belongs to the IL-6 superfamily.
Post-translational modifications	N- and O-glycosylated.
DISEASE	Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	This gene encodes a cytokine that functions in inflammation and the maturation of B cells. In addition, the encoded protein has been shown to be an endogenous pyrogen capable of inducing fever in people with autoimmune diseases or infections. The protein is primarily produced at sites of acute and chronic inflammation, where it is secreted into the serum and induces a transcriptional inflammatory response through interleukin 6 receptor, alpha. The functioning of this gene is implicated in a wide variety of inflammation-associated disease states, including susceptibility to diabetes mellitus and systemic juvenile rheumatoid arthritis. [provided by RefSeq, Jun 2011].

Additional Information


Dilution	WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
-----------------	--

Format	0.01M TBS(pH7.4) with 1% BSA, 0.09% (W/V) sodium azide and 50% Glyce
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.


Background

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Images



HUVEC (H) cells were treated with or without LPS (0.5 µg/ml, 24h) and Brefeldin A (300 ng/ml, 20h), 25 µg total protein per lane of cell lysates (see on figure) probed with human IL-6 monoclonal antibody, unconjugated (AP94142) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded Human Ovarian Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with human IL-6 Monoclonal Antibody, Unconjugated (AP94142) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Mouse, sp-0024) and DAB (C-0010) staining.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.